Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: A multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG)

Melanoma Research

Volumn 13, Issue 5, 2003, Pages 531-536

  Zimpfer Rechner, Christine ^a   Hofmann, Udo ^a   Figl, Robert ^a   Becker, Jürgen C ^b   Trefzer, Uwe ^c   Keller, Ivonne ^d   Hauschild, Axel ^e   Schadendorf, Dirk ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HELIOS KLINIKUM ERFURT   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Carboplatin; Overall survival; Second line; Taxane; Toxicity

Indexed keywords

CARBOPLATIN; CIMETIDINE; CLEMASTINE; DEXAMETHASONE; PACLITAXEL; RANITIDINE;

ADULT; ALOPECIA; ANEMIA; ARTICLE; ATRIOVENTRICULAR BLOCK; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; LEUKOPENIA; MALE; MELANOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; OUTPATIENT; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; ULCER; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MELANOMA; PACLITAXEL; TIME FACTORS; TREATMENT OUTCOME;

EID: 0142057351     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200310000-00012     Document Type: Article

References (26)

1. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20:1818-1825.
2. Stadelmann WK, Rapaport DP, Soong S-J, Reintgen DS, Buzaid A, Balch CM. Prognostic clinical and pathological features. In: Balch CM, Houghton AN, Sober AJ, Soong S-J (editors): Cutaneous Melanoma, 3rd edition. St Louis: Quality Medical Publishing; 1998, pp. 11-36.
3. Sirott MN, Bajorin DF, Wong, GYC, Tao Y, Chapman PB, Templeton MA, Houghton AN. Prognostic factors in patients with metastatic melanoma. A multivariate analysis. Cancer 1993; 72:3091-3098.
4. Schadendorf D. Is there a standard in the palliative treatment of melanoma? Onkologie 2002; 25:74-76.
5. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1995; 13:1860-1870.
6. D'Addario G, Morant R, Böhme C, Czerny T. Feasibility and toxicity of weekly paclitaxel-carboplatin in 131 patients with pretreated and non-pretreated solid tumors. Onkologie 2002; 25:152-157.
7. Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48:794-847.
8. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93:2325-2327.
9. Schiff PB, Horwitz SB. Tubulin: a target for chemotherapeutic agents. In: Sartorelli A (editor): Molecular Actions and Targets for Cancer Chemotherapeutic Agents. New York: Academic Press; 1980, pp. 483-507.
10. Wiernik PH, Schwartz EL, Einzig A, Straumann JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5 (8):1232-1239.
11. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9 (1):59-64.
12. Hodi FS, Soiffer RJ, Clark J, Finkelstein D, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. American Society of Clinical Oncology 1999, abstract 2128.
13. Zonder JA, LoRosso P, Heilbrun L, Flaherty LE. Phase II trial of weekly paclitaxel as 2nd line treatment of metastatic malignant melanoma. American Society of Clinical Oncology 2000, abstract 2249.
14. Atzpodien J, Lopez Hanninen E, Kirchner H, Franzke A, Korfer A, Volkenandt M, et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995; 31A:876-881.
15. Huisman C, Postmus PE, Giaccone G, Smit EF. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 1999; 25:199-205.
16. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9:389-393.
17. Guven K, Kittler H, Wolff K, Pehamberger H. Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients. Melanoma Res 2001; 11:411-415.
18. Mulder NH, Sleijfer DTh, de Vries EGE, Schraffordt Koops H, Willemse PHB. Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma. J Cancer Res Clin Oncol 1990; 116:301-302.
19. Löffler TM, Freund W, Lipke J, Hausamen TU. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin Oncol 1996; 23 (suppl 16):32-34.
20. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensivity reactions from Taxol. J Clin Oncol 1990; 8:1263-1268.
21. Morere JF, Piperno-Neumann S, Coulon MA, Vaylet F, L'Her P, Brunet A, et al. Dose-finding study of paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Anticancer Drugs 2000; 11:541-548.
22. Wiernik PH, Einzig AI. Taxil in melanoma. J Natl Cancer Inst Monogr 1993; 15:185-187.
23. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15:187-192.
24. Thigpen T. Second-line therapy for ovarian carcinoma: general concepts. In: 1999 Spring Educational Book. Alexandria: American Society of Clinical Oncology; 1999, pp. 564-566.
25. Rowinsky EK, Eisenhauer EA, Chaundhry V, Arbuck SG, Donhower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20 (4 Suppl 3):1-15.
26. Greco FA, Thomas M, Hainsworth JD. One-hour paclitaxel infusions: review of safety and efficacy. Cancer J Sci Am 1999; 5:179-191.